Actively Recruiting
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
Led by Neurology Center of New England P.C. · Updated on 2024-11-18
20
Participants Needed
1
Research Sites
163 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate
CONDITIONS
Official Title
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Aged 55-80 years old
- Diagnosis of relapsing forms of multiple sclerosis according to the 2017 Revised McDonald criteria
- Anticipated to begin treatment with or newly treated with ublituximab within 6 months prior to study entry according to the local label
You will not qualify if you...
- Active participation in an interventional clinical trial for multiple sclerosis
- Received initial dose of ublituximab more than 6 months prior to study entry
- History of life-threatening infusion reaction on any anti-CD20 therapy
- Clinically significant chronic or ongoing active viral, bacterial, or fungal infection requiring long-term systemic treatment
- History of recurrent infection within 6-12 months prior to starting ublituximab
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Neurology Center of New England P.C.
Foxborough, Massachusetts, United States, 02035
Actively Recruiting
Research Team
S
Salvatore Napoli, MD
CONTACT
R
Rachel ODonnell, BS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here